Amedisys Company Profile (NASDAQ:AMED)

About Amedisys (NASDAQ:AMED)

Amedisys logoAmedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness. The Personal care segment provides patients with assistance with the essential activities of daily living.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Home Healthcare Services
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:AMED
  • CUSIP: 02343610
  • Web: www.amedisys.com
Capitalization:
  • Market Cap: $1.70224 billion
  • Outstanding Shares: 33,862,000
Average Prices:
  • 50 Day Moving Avg: $51.65
  • 200 Day Moving Avg: $55.05
  • 52 Week Range: $34.58 - $65.91
P/E:
  • Trailing P/E Ratio: 42.97
  • Foreward P/E Ratio: 20.69
  • P/E Growth: 1.18
Sales & Book Value:
  • Annual Revenue: $1.45 billion
  • Price / Sales: 1.17
  • Book Value: $14.54 per share
  • Price / Book: 3.46
Profitability:
  • EBITDA: $105.65 million
  • Net Margins: 2.70%
  • Return on Equity: 13.71%
  • Return on Assets: 8.56%
Debt:
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 1.21%
  • Quick Ratio: 1.21%
Misc:
  • Average Volume: 408,949 shs.
  • Beta: 0.87
  • Short Ratio: 4.52
 

Frequently Asked Questions for Amedisys (NASDAQ:AMED)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys's revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $0.42 earnings per share. View Amedisys' Earnings History.

When will Amedisys make its next earnings announcement?

Amedisys is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Amedisys.

Where is Amedisys' stock going? Where will Amedisys' stock price be in 2017?

10 brokerages have issued 1-year target prices for Amedisys' shares. Their predictions range from $50.00 to $60.00. On average, they expect Amedisys' stock price to reach $56.20 in the next twelve months. View Analyst Ratings for Amedisys.

What are analysts saying about Amedisys stock?

Here are some recent quotes from research analysts about Amedisys stock:

  • 1. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
  • 2. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:

  • Paul B. Kusserow, President, Chief Executive Officer, Director
  • Gary D. Willis, Chief Financial Officer
  • Christopher T. Gerard, Chief Operating Officer
  • Lawrence R. Pernosky, Chief Human Resource Officer
  • Scott G. Ginn, Chief Accounting Officer
  • Michael Paul North, Chief Information Officer
  • David B. Pearce, Chief Compliance Officer
  • David L. Kemmerly, General Counsel
  • Stephen E. Seim, Chief Strategy Officer
  • Susan Sender, Chief Clinical Operations Officer

Who owns Amedisys stock?

Amedisys' stock is owned by a number of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.06%) and Quantitative Systematic Strategies LLC (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky, North Tide Capital, Llc and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Who bought Amedisys stock? Who is buying Amedisys stock?

Amedisys' stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Quantitative Systematic Strategies LLC. View Insider Buying and Selling for Amedisys.

How do I buy Amedisys stock?

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of Amedisys stock can currently be purchased for approximately $50.27.


MarketBeat Community Rating for Amedisys (NASDAQ AMED)
Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  341 (Vote Underperform)
Total Votes:  510
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amedisys (NASDAQ:AMED) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $56.20 (11.80% upside)
Consensus Price Target History for Amedisys (NASDAQ:AMED)
Price Target History for Amedisys (NASDAQ:AMED)
Analysts' Ratings History for Amedisys (NASDAQ:AMED)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Royal Bank Of CanadaReiterated RatingHoldN/AView Rating Details
10/12/2017Jefferies Group LLCReiterated RatingBuy$60.00N/AView Rating Details
10/9/2017SunTrust Banks, Inc.Reiterated RatingBuy$60.00N/AView Rating Details
10/4/2017Robert W. BairdReiterated RatingHold$50.00LowView Rating Details
9/15/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$60.00LowView Rating Details
8/21/2017Bank of America CorporationInitiated CoverageNeutral -> Neutral$55.00LowView Rating Details
7/26/2017MizuhoDowngradeBuy -> Neutral$50.00HighView Rating Details
5/4/2017StephensBoost Price TargetEqual Weight$50.00 -> $54.00LowView Rating Details
5/3/2017Benchmark Co.Reiterated RatingHold -> Hold$50.00 -> $57.00HighView Rating Details
1/17/2017Craig HallumSet Price TargetBuy$60.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
1/11/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$42.00 -> $45.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Amedisys (NASDAQ:AMED)
Earnings by Quarter for Amedisys (NASDAQ:AMED)
Earnings History by Quarter for Amedisys (NASDAQ AMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.53N/AView Earnings Details
7/26/2017Q2 2017$0.50$0.62$380.80 million$378.80 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.41$0.47$370.03 million$370.46 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.36$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$322.67 million$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.17$0.28$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.17$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114($0.06)($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amedisys (NASDAQ:AMED)
2017 EPS Consensus Estimate: $2.03
2018 EPS Consensus Estimate: $2.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.40$0.42$0.41
Q2 20173$0.48$0.55$0.51
Q3 20173$0.53$0.54$0.53
Q4 20173$0.57$0.60$0.58
Q1 20182$0.54$0.58$0.56
Q2 20182$0.62$0.63$0.63
Q3 20182$0.64$0.66$0.65
Q4 20182$0.67$0.70$0.69
Q1 20191$0.68$0.68$0.68
Q2 20191$0.71$0.71$0.71
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amedisys (NASDAQ:AMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Amedisys (NASDAQ:AMED)
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 96.55%
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017David B PearceInsiderSell1,000$50.00$50,000.00View SEC Filing  
8/3/2017Bruce D PerkinsDirectorBuy2,000$46.60$93,200.00View SEC Filing  
5/25/2017Bruce D PerkinsDirectorBuy500$59.69$29,845.00View SEC Filing  
5/12/2017Jake L NettervilleDirectorSell10,000$60.00$600,000.00View SEC Filing  
5/10/2017Lawrence R PernoskyInsiderSell11,500$58.97$678,155.00View SEC Filing  
5/9/2017Lawrence R PernoskyInsiderSell11,500$58.78$675,970.00View SEC Filing  
5/8/2017Scott G GinnInsiderSell23,828$58.62$1,396,797.36View SEC Filing  
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.00View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.00View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.50View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Amedisys (NASDAQ:AMED)
Latest Headlines for Amedisys (NASDAQ:AMED)
Source:
Loading headlines, please wait.

Social

Chart

Amedisys (AMED) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.